COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024 … [Read more...] about COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024
COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis … [Read more...] about COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives … [Read more...] about COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors … [Read more...] about COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors
COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer … [Read more...] about COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures … [Read more...] about COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures
COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer … [Read more...] about COUR Pharmaceuticals Appoints Dannielle Appelhans as Chief Operating Officer
COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director … [Read more...] about COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director